Art Krieg, Checkmate Pharmaceuticals

Re­gen­eron buys Art Krieg’s biotech start­up for a dis­count price, boost­ing I/O pipeline

Jump­ing in­to the M&A game, Re­gen­eron has scooped up a beat­en down Check­mate Phar­ma­ceu­ti­cals for $250 mil­lion in cash, bag­ging its lead drug for melanoma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.